Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Dades bibliogràfiques
Autors principals:	DiNardo, CD, Dohner, H, Zeidan, AM, Schuh, AC, Vyas, P, Stein, EM, Wei, AH, de Botton, S, Chen, C, Lord-Bessen, J, Martin-Regueira, P, Lersch, F, Gong, J, Guo, S, Shi, L, Montesinos, P
Format:	Conference item
Idioma:	English
Publicat:	American Society of Hematology 2021

Ítems similars

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)
per: Dinardo, CD, et al.
Publicat: (2022)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
per: DiNardo, CD, et al.
Publicat: (2021)

Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia
per: Risueño, A, et al.
Publicat: (2023)

Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial
per: DiNardo, CD, et al.
Publicat: (2021)

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
per: Stein, EM, et al.
Publicat: (2017)

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
per: Risueño, A, et al.
Publicat: (2024)

Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib
per: Vyas, P, et al.
Publicat: (2018)

A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AML)
per: Papayannidis, C, et al.
Publicat: (2021)

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial
per: De Botton, S, et al.
Publicat: (2022)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
per: de Botton, S, et al.
Publicat: (2022)

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
per: Stein, EM, et al.
Publicat: (2018)

Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia
per: Quek, L, et al.
Publicat: (2017)

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
per: DiNardo, C, et al.
Publicat: (2019)

AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial
per: DiNardo, CD, et al.
Publicat: (2022)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
per: Anuhar Chaturvedi, et al.
Publicat: (2020-04-01)

Differentiation Syndrome in a Patient With NSCLC Harboring IDH2 Mutation Treated With Enasidenib: Case Report
per: Bhoomika Sukhadia, MD, et al.
Publicat: (2024-10-01)

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaResearch in context
per: Verónica Rey, et al.
Publicat: (2024-04-01)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
per: Mondesir J, et al.
Publicat: (2016-09-01)

Self-reported health-related quality of life (HRQoL) and factors affecting HRQoL among individuals with health insurance in Iran
per: Ali Kazemi Karyani, et al.
Publicat: (2016-10-01)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
per: Lachowiez, CA, et al.
Publicat: (2022)

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
per: Lachowiez, CA, et al.
Publicat: (2023)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
per: Ghayas C. Issa, et al.
Publicat: (2021-06-01)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
per: Claudio Cerchione, et al.
Publicat: (2021-03-01)

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies
per: Lachowiez, CA, et al.
Publicat: (2021)

Health-Related Quality of Life (HRQoL) in Young Adults with Strabismus in India
per: Surendra P Sah, et al.
Publicat: (2017-02-01)

The challenges of classical galactosemia: HRQoL in pediatric and adult patients
per: Merel E. Hermans, et al.
Publicat: (2023-06-01)

Higher perceived HRQoL in Moroccan children with asthma and their parents
per: Monique Theodora Maria Veenstra-van Schie, et al.
Publicat: (2015-05-01)

Impact of depression on sexual dysfunction and HRQoL in CAD patients
per: Tasic Ivan, et al.
Publicat: (2014-02-01)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
per: Lachowiez, C, et al.
Publicat: (2022)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
per: Krell, D, et al.
Publicat: (2011)

HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
per: Tri Wahyu Martanto, et al.
Publicat: (2023-10-01)

Socioeconomic inequalities in HRQoL in England: an age-sex stratified analysis
per: Paul Schneider, et al.
Publicat: (2022-08-01)

The association between diabetes mellitus and HRQoL of older people in Shanghai
per: Shiyin Tian, et al.
Publicat: (2021-11-01)

Insomnia and HRQoL of Indonesians with Chronic Pain: The Role of Catastrophizing and Anxiety
per: Fariza Nur Shabrina, et al.
Publicat: (2021-05-01)

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
per: Keith W. Pratz, et al.
Publicat: (2022-04-01)

Research progress of IDH1 and IDH2 mutations in gliomas
per: Shan-shan ZHANG, et al.
Publicat: (2015-11-01)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
per: Yusuke Daido, et al.
Publicat: (2023-09-01)

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
per: Emir, U, et al.
Publicat: (2015)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
per: Daniel Krell, et al.
Publicat: (2011-01-01)

Health-Related Quality of Life (HRQoL) of Patients with Tuberculosis: A Review
per: Sandul Yasobant, et al.
Publicat: (2022-07-01)